Literature DB >> 10981175

Angiotensin converting enzyme inhibitors: are they preferred first-line therapy?

S P Glasser1.   

Abstract

In patients with hypertension, the primary goal is to reduce elevated blood pressure. All of the currently available and approved antihypertensive therapies are, by and large, equally efficacious. Some patient groups and individual patients may, however, respond differentially, and as a result one therapy may be more optimal than another. Overall, for uncomplicated hypertension and particularly for isolated systolic hypertension, diuretics should be considered for first-line therapy. However, comorbid conditions (which occur in > 50% of hypertensive patients) may prompt the need for a more ideal first-line therapy (eg, hypertension with diabetic nephropathy or with left ventricular dysfunction). Regardless, most patients with hypertension will require multidrug therapy to achieve the blood pressure goal, and an angiotensin converting enzyme (ACE) inhibitor may well be part of that therapy. Many going outcome trials comparing the newer therapies (such as ACE inhibitors) with diuretic-based therapy may redefine or clarify the use of different antihypertensive regimens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10981175     DOI: 10.1007/s11906-000-0043-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  25 in total

1.  Arterial stiffness and the development of hypertension. The ARIC study.

Authors:  D Liao; D K Arnett; H A Tyroler; W A Riley; L E Chambless; M Szklo; G Heiss
Journal:  Hypertension       Date:  1999-08       Impact factor: 10.190

Review 2.  Implications for cost-effectiveness. Combination therapy for systemic hypertension.

Authors:  N M Kaplan
Journal:  Am J Cardiol       Date:  1995-09-15       Impact factor: 2.778

Review 3.  The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia.

Authors:  C J Pepine
Journal:  Am J Cardiol       Date:  1998-11-19       Impact factor: 2.778

Review 4.  Vascular compliance and cardiovascular disease: a risk factor or a marker?

Authors:  S P Glasser; D K Arnett; G E McVeigh; S M Finkelstein; A J Bank; D J Morgan; J N Cohn
Journal:  Am J Hypertens       Date:  1997-10       Impact factor: 2.689

Review 5.  Hypertension, hypertrophy, hormones, and the heart.

Authors:  S P Glasser
Journal:  Am Heart J       Date:  1998-02       Impact factor: 4.749

6.  Hypertension in the elderly: only the end of the beginning.

Authors:  E D Frohlich
Journal:  Hypertension       Date:  1994-03       Impact factor: 10.190

7.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

Review 9.  National High Blood Pressure Education Program Working Group Report on Hypertension in the Elderly. National High Blood Pressure Education Program Working Group.

Authors: 
Journal:  Hypertension       Date:  1994-03       Impact factor: 10.190

Review 10.  Atherosclerosis: risk factors and the vascular endothelium.

Authors:  S P Glasser; A P Selwyn; P Ganz
Journal:  Am Heart J       Date:  1996-02       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.